A seed oil supplying an uncommon omega-6 fat alongside plant omega-3 fats. The most consistent finding is in blood chemistry: it raises that fat in blood and cell membranes and lowers one inflammatory signalling molecule. Joint, dry eye and nerve findings come mostly from the fatty acid itself. Risks are mild and mostly digestive. Clinical payoff stays uncertain. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Dihomo-γ-linolenic acid to arachidonic acid ratio (plasma or red cell) | No established target; a clear rise from own baseline by 12 weeks | The direct pharmacodynamic readout — confirms the oil is doing what it is taken to do |
| High-sensitivity C-reactive protein | <1.0 mg/L (functional); <0.5 mg/L preferred in longevity practice | Captures whether the membrane shift translates into lower systemic inflammation |
| Low-density lipoprotein cholesterol | <100 mg/dL (functional); <70 mg/dL with cardiovascular risk | The lipid fraction that moved in the one head-to-head trial against fish oil |
| Triglycerides | <80 mg/dL (functional) | Second lipid endpoint reported to respond, and a marker of the metabolic state that suppresses the desaturase enzymes |
| International normalised ratio | Within the individual's prescribed therapeutic window; 0.8–1.2 if not anticoagulated | Detects the additive platelet and clotting effect before bruising or bleeding appears |
| Omega-3 index (red cell eicosapentaenoic acid plus docosahexaenoic acid) | 8–12% | Establishes whether marine omega-3 intake is adequate, which determines how much gamma-linolenic acid is needed |
Cadence: Fatty acid panel and high-sensitivity C-reactive protein at baseline, repeated at 12 weeks, then every 6–12 months while use continues. For those on anticoagulants, the international normalised ratio is checked at 2 weeks and 6 weeks after starting and after every dose change.